Product Overview
The 2R/3ml Clear RTU Glass Vials from Vialab Pharmaceutical Packaging Co., Ltd. are premium-grade, ready-to-use sterile containers designed for pharmaceutical injection and storage applications. Each vial is meticulously washed, depyrogenated, and ETO (ethylene oxide) sterilized, then sealed with a rubber stopper and cap—delivering a complete, turnkey primary packaging solution that arrives at your facility ready for immediate filling.
The global market for Ready-to-Use Pharmaceutical Glass Primary Packaging was valued at US$ 5,011 million in 2024 and is projected to reach US$ 7,528 million by 2031, growing at a CAGR of 6.3%. The pre-sterilized ready-to-use vials segment alone is forecast to grow from US$ 1,145 million in 2025 to US$ 2,655 million by 2032, at an impressive CAGR of 12.76%. This rapid growth reflects the pharmaceutical industry’s accelerating shift toward RTU formats that eliminate in-house washing, depyrogenation, and sterilization—streamlining workflows, reducing contamination risks, and accelerating time-to-market.
Vialab’s 2R/3ml RTU vials are positioned to meet this surging demand, offering pharmaceutical companies, biotech firms, and contract manufacturing organizations (CMOs) a reliable, compliant, and cost-effective primary packaging solution for injectable drugs, vaccines, and biologics.
What Are Ready-to-Use (RTU) Vials?
Ready-to-use (RTU) pharmaceutical glass primary packaging refers to pre-sterilized glass containers—such as vials, syringes, ampoules, and cartridges—that are delivered to pharmaceutical manufacturers in a sterile, ready-for-filling condition. In RTU systems, the packaging is washed, depyrogenated, and sterilized by the packaging supplier off-site, so that the only in-house process remaining is to fill and finish the container.
This model eliminates significant operational constraints for pharmaceutical companies, including:
- Capital expenditure (CAPEX) savings – No need to invest in washing, depyrogenation, and sterilization equipment
- Reduced labor burden – Lower operator intervention and streamlined workflows
- Minimized contamination risks – Components are processed and packaged in controlled environments
- Accelerated time-to-market – Ready-to-fill vials support both early drug development and commercial production
The Vialab 2R/3ml RTU vials are designed for small to large batch aseptic parenteral packaging, making them suitable for pharmaceutical and contract manufacturing entities at every scale.
Depyrogenation – Ensuring Endotoxin-Free Packaging
What Is Depyrogenation?
Depyrogenation is the process of removing or destroying pyrogens—fever-inducing bacterial endotoxins—from pharmaceutical packaging components. Bacterial endotoxins are lipopolysaccharides (LPS) from the cell walls of Gram-negative bacteria that can cause severe febrile reactions in patients if introduced into injectable drugs.
For glass vials, the industry standard for depyrogenation is dry heat treatment. The European Pharmacopoeia specifies dry heat at 250°C for 30 minutes, or 200°C for 60 minutes for depyrogenation of glass. Dry heat is the established method of depyrogenation within the pharmaceutical industry. Glass containers are capable of withstanding sterilization temperatures up to 500°C without noticeable degradation.
Vialab’s Depyrogenation Process
Each Vialab 2R/3ml glass vial is subjected to a validated dry heat depyrogenation process that ensures bacterial endotoxins are reduced to acceptable limits—typically ≤ 0.25 EU/ml. This process is performed in accordance with USP <85> (Bacterial Endotoxins Test) and EP 2.6.1 requirements.
Following depyrogenation, the vials are:
- Washed with WFI (Water for Injection)
- Dried with impulsion of compressed air
- Vacuum-packaged within an ISO cleanroom environment
ETO Sterilization – Validated to ISO 11135
Why Ethylene Oxide (ETO) Sterilization?
Ethylene oxide (EtO) sterilization is a low-temperature, highly effective sterilization method widely used for pharmaceutical packaging that cannot withstand the high temperatures of steam or dry heat sterilization. EtO penetrates packaging materials and kills all microorganisms—including bacterial spores—by alkylating proteins and DNA.
ISO 11135 Compliance
The Vialab 2R/3ml RTU vials are sterilized using a validated EtO process that meets ISO 11135 requirements—the international standard for the development, validation, and routine control of ethylene oxide sterilization processes for healthcare products.
ISO 11135 requires manufacturers to:
- Define a robust process window
- Prove it with a defensible validation
- Control it routinely in production
The EtO sterilization process for Vialab vials is validated to achieve a Sterility Assurance Level (SAL) of 10⁻⁶—meaning the probability of a single viable microorganism remaining on the vial is less than one in one million. This is the industry-standard SAL for sterile pharmaceutical packaging.
Residual Limits & Patient Safety
Following EtO sterilization, all Vialab vials undergo rigorous aeration to reduce residual ethylene oxide and ethylene chlorohydrin (ECH) to safe levels. ISO 10993-7 specifies allowable limits (AL) for residual EO and ECH in sterilized medical devices. Vialab’s validated process ensures that all residual levels are well within these internationally recognized safety limits, protecting both drug product integrity and patient safety.
Regulatory Compliance & Quality Standards
The Vialab 2R/3ml RTU glass vials meet all current requirements of applicable ISO standards and pharmacopoeias:
Pharmacopoeial Compliance
- USP <71> (Sterility Tests) – Each lot is verified for sterility
- USP <85> (Bacterial Endotoxins Test) – Endotoxin levels are controlled
- USP <660> (Containers—Glass) – Glass quality and chemical resistance
- EP 2.6.1 (Bacterial Endotoxins) – European Pharmacopoeia standard
- EP 2.6.14 (Sterility) – European Pharmacopoeia sterility standard
ISO Standards
- ISO 11135 – Ethylene oxide sterilization validation
- ISO 10993-7 – EO residual limits
- ISO 11040-7 – Prefilled syringes—packaging systems
- ISO 21882 – RTU vial packaging standards
Quality Management
- cGMP (Current Good Manufacturing Practice) – Manufactured in accordance with cGMP
- ISO 13485 – Medical device quality management
- Certificate of Analysis (COA) – Each shipment includes a COA
Vialab’s manufacturing facilities include advanced production lines and cleanroom environments, ensuring consistent quality, integrity, and compliance for global healthcare partners.
Technical Specifications
| Parameter | Specification |
|---|---|
| Product Name | Clear RTU Glass ETO Sterilized Washed Sterile Vial |
| Model Number | 2R / 3 ml |
| Capacity | 2R / 3 ml |
| Dimensions | 16 × 35 mm |
| Base Material | Glass (Type I borosilicate) |
| Body Material | Glass |
| Shape | Round |
| Sealing Type | Rubber Stopper |
| Surface Handling | Hot stamping |
| Printing Handling | Labels |
| Cap Color | Customized Colors |
| Sterilization | ETO (Ethylene Oxide) – ISO 11135 validated |
| Depyrogenation | Dry heat – USP <85> / EP 2.6.1 compliant |
| Sterility | SAL ≤ 10⁻⁶ – USP <71> / EP 2.6.14 compliant |
| Packaging | Carton |
| MOQ | 100 pieces |
| OEM/ODM | Acceptable |
| Logo | Customized Logo Acceptable |
| Usage | Injection & Storage |
| Industrial Use | Medicine |
Key Benefits for Pharmaceutical Manufacturers
1. Eliminate In-House Preparation
By choosing Vialab RTU vials, pharmaceutical manufacturers eliminate the need for in-house washing, depyrogenation, and sterilization. This removes significant operational bottlenecks and allows manufacturers to focus on their core competencies—drug development and fill-finish operations.
2. Reduce Contamination Risks
RTU vials are processed, packaged, and sterilized in controlled environments, minimizing contamination risks at every stage. The vials are vacuum-packed and remain sterile until the moment of filling.
3. Accelerate Time-to-Market
RTU vials support both early drug development and commercial production. By removing the upfront operational constraints, Vialab’s RTU vials help pharmaceutical companies bring products to market faster.
4. Lower Total Cost of Ownership
By outsourcing non-core activities such as washing and sterilization, pharmaceutical companies can reduce fixed costs and lower their overall footprint. The simplified supply chain and reduced operator intervention translate to significant cost savings across the product lifecycle.
5. Flexible Order Quantities
With a minimum order quantity (MOQ) of just 100 pieces, the Vialab 2R/3ml RTU vials are accessible to a wide range of customers—from research laboratories and small-scale clinical trials to large commercial production.
Applications
The Vialab 2R/3ml RTU glass vials are suitable for a broad spectrum of pharmaceutical and medical applications:
Injectable Drugs
- Vaccines – Sterile storage and administration
- Biologics – Protein-based therapeutics requiring pristine container integrity
- Insulin – Diabetes management
- Peptide therapeutics – GLP-1 therapies and other peptide drugs
- Antibiotics – Parenteral administration
- Generic injectables – Large-volume production
Lyophilized Products
- Freeze-dried pharmaceuticals – Vials designed to withstand lyophilization processes
Research & Development
- Clinical trial materials – Small-batch production for early-phase studies
- Laboratory storage – Sample and reagent storage
Customization Options
Vialab offers comprehensive OEM and ODM customization services for RTU glass vials:
Available Customizations
- Cap color – Customized colors available
- Logo printing – Customized logo acceptable
- Labeling – Custom labels and printing
- Surface handling – Hot stamping options
- Packaging configurations – Custom carton packaging
Low MOQ for Trials
With an MOQ of just 100 pieces, pharmaceutical companies can easily trial the Vialab RTU vials in small-batch production before scaling to commercial volumes.
Why Choose Vialab?
Vialab Pharmaceutical Packaging Co., Ltd. specializes in the design and manufacture of high-quality drug delivery and packaging components. From injection pens to sterile vials, every product is engineered to meet strict pharmaceutical standards. Our comprehensive product portfolio includes:
- Injection Pens (Disposable & Reusable)
- Glass Vials & Tubes (Parenteral Grade, Precise Dimensions)
- Sterile Vials (Ready-To-Use, Washed & Sterilized)
- Aluminum & Aluminum-Plastic Caps (Tamper-Evident, Various Sizes)
- Customized Packaging Solutions (Pen Cases, Accessories, Etc.)
- Strict Quality Control (ISO/GMP Compliant)
With advanced production lines and cleanroom facilities, we ensure consistent quality, integrity, and compliance for global healthcare partners.
Conclusion
The Vialab 2R/3ml Clear RTU Glass Vials represent the convergence of rigorous quality standards, validated sterilization processes, and operational efficiency. Depyrogenated to USP <85> standards, ETO sterilized to ISO 11135 requirements, and delivered ready-to-use with stopper and cap, these vials eliminate the need for in-house preparation while ensuring the highest levels of sterility assurance and patient safety.
In a pharmaceutical glass packaging market valued at US$ 23 billion and growing, Vialab’s RTU vials offer pharmaceutical manufacturers, biotech firms, and CMOs a reliable, compliant, and cost-effective primary packaging solution for injectable drugs, vaccines, and biologics.
Whether you are developing a new biologic, scaling a vaccine production line, or manufacturing generic injectables, Vialab’s 2R/3ml RTU glass vials deliver the quality, consistency, and regulatory compliance you need—ready to use, right out of the box.
For inquiries about the 2R/3ml RTU Glass Vials, OEM/ODM customization, or other pharmaceutical packaging solutions, contact Vialab Pharmaceutical Packaging Co., Ltd. today.